News

Investor Awarded Six Figures After Annuity Loss Against Citizens

Investor Awarded Six Figures After Annuity Loss Against Citizens

Significant Award for Retiree in Annuity Dispute with Citizens Securities

Shepherd Smith Edwards & Kantas is proud to share a recent victory in a FINRA arbitration, where our dedicated annuity fraud lawyers successfully represented a retiree. This elderly client faced significant financial losses due to an investment in a Colorado Bankers Life Insurance annuity, commonly referred to as a CB Life annuity.

The Details of the Case

The arbitration panel ruled in favor of our client, ordering Citizens Securities to pay a total award of $152,382.41 in compensatory damages, along with an additional $48,762.37 to cover attorney's fees. This substantial amount underscores the seriousness of the client's grievances and the mismanagement of their investments.

During the arbitration, our client asserted claims such as breach of contract and fiduciary duty. The evidence indicated that the CB Life annuity was improperly recommended to them by their broker at Citizens Securities, causing undue financial harm. Although the arbitration ruling did not explicitly explain the basis for the damages awarded, it is believed that a lack of transparency regarding investment status played a key role.

Impact on Retired Investors

Investors like our client were marginalized due to the broker’s failure to inform them of critical developments related to their investments. These omissions created missed opportunities for the investor to divest before experiencing irreversible losses.

Challenging Experiences for CB Life Annuity Investors

At Shepherd Smith Edwards & Kantas, we are actively assisting more than 100 investors in seeking redress against broker-dealers like Citizens Securities for their CB Life annuity losses. Our firm understands the financial distress faced by many retired individuals who counted on these investments for their livelihood.

Moreover, numerous clients have reported feeling left in the dark regarding their CB Life annuities, which further deepens our commitment to seeking justice for those affected. The attrition of funds in annuities after the company faced regulatory actions has left many retired investors without the financial support they expected to receive.

Longstanding Advocacy for Investors

For over three decades, our firm has championed the rights of investors both in the U.S. and internationally against broker-dealers and investment advisors. Over the years, we've effectively recovered hundreds of millions of dollars for our clients, enabling them to reclaim their financial stability.

Legal Assistance for Affected CB Life Annuity Investors

If you have experienced losses due to a Colorado Bankers Life annuity, it is crucial to understand your legal options. Our team of experienced attorneys can assess your case and advocate for the compensation you deserve. Don’t hesitate to contact us for a consultation.

Frequently Asked Questions

What was the outcome of the FINRA arbitration for the retiree?

The arbitration panel awarded the retiree a total of $152,382.41 in damages, along with attorney's fees amounting to $48,762.37.

What kind of claims were made against Citizens Securities?

The claims included breach of contract, breach of fiduciary duty, misrepresentations, and negligence regarding the CB Life annuity investment.

How did Shepherd Smith Edwards & Kantas assist the retiree?

Our law firm represented the retiree in the FINRA arbitration, advocating for their rights and achieving a favorable outcome.

Why are many investors concerned about CB Life annuities?

Investors have reported significant losses and a lack of communication from their broker-dealers regarding the status of their CB Life annuities, leading to financial distress, especially among retirees.

What should I do if I experienced losses in a CB Life annuity?

If you have suffered financial losses from a CB Life annuity, consider reaching out for legal support to explore potential claims against the financial institution involved.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles